Published in Cancer Cell on January 14, 2013
Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood (2015) 1.70
B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol (2013) 1.39
Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance. Blood (2014) 1.29
Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood (2014) 1.15
Protein kinase C and cancer: what we know and what we do not. Oncogene (2013) 1.09
The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res (2014) 1.04
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta (2015) 0.98
The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene (2015) 0.87
Role of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia development. Onco Targets Ther (2014) 0.86
The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer (2016) 0.86
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. Blood (2014) 0.84
The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. Ann Hematol (2013) 0.83
Cancer associated fibroblasts in hematological malignancies. Oncotarget (2015) 0.79
Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells. J Biol Chem (2015) 0.78
Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation. Proc Natl Acad Sci U S A (2016) 0.76
NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms. Blood Rev (2016) 0.76
Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways. Oncotarget (2015) 0.76
Constitutive activation of NF-κB signaling by NOTCH1 mutations in chronic lymphocytic leukemia. Oncol Rep (2015) 0.76
Stroma-Derived Connective Tissue Growth Factor Maintains Cell Cycle Progression and Repopulation Activity of Hematopoietic Stem Cells In Vitro. Stem Cell Reports (2015) 0.76
Phenotypic and Functional Alterations of Hematopoietic Stem and Progenitor Cells in an In Vitro Leukemia-Induced Microenvironment. Int J Mol Sci (2017) 0.75
Protein kinase C in cellular transformation: a valid target for therapy? Biochem Soc Trans (2014) 0.75
Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment. Vaccines (Basel) (2016) 0.75
Cordycepin disrupts leukemia association with mesenchymal stromal cells and eliminates leukemia stem cell activity. Sci Rep (2017) 0.75
Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKCα subversion induces up-regulation of PKCβII expression in B lymphocytes. Haematologica (2015) 0.75
Transcriptional mechanism of vascular endothelial growth factor-induced expression of protein kinase CβII in chronic lymphocytic leukaemia cells. Sci Rep (2017) 0.75
Microenvironment: an accommodating host. Nat Rev Cancer (2013) 0.75
In vivo hematopoietic Myc activation directs a transcriptional signature in endothelial cells within the bone marrow microenvironment. Oncotarget (2015) 0.75
Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol (2001) 31.56
The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell (1992) 30.02
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
Signaling to NF-kappaB. Genes Dev (2004) 19.78
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med (2000) 16.30
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med (2003) 6.82
Tumor stroma and regulation of cancer development. Annu Rev Pathol (2006) 6.66
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet (2011) 6.43
Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell (2010) 6.33
Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A (2002) 4.86
The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell (2010) 4.71
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood (2000) 4.18
Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood (1998) 4.07
Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature (2003) 3.96
NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol Cell (2000) 3.60
Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer (2009) 3.49
Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: a tool for efficient genetic engineering of mammalian genomes. Proc Natl Acad Sci U S A (2002) 3.01
Immunodeficiency in protein kinase cbeta-deficient mice. Science (1996) 2.79
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol (2012) 2.59
Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood (2002) 2.14
PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol (2002) 2.03
A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol (2005) 1.73
Expression and properties of two types of protein kinase C: alternative splicing from a single gene. Science (1987) 1.67
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol (2007) 1.63
Stromal cell lines from mouse aorta-gonads-mesonephros subregions are potent supporters of hematopoietic stem cell activity. Blood (2002) 1.48
Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia (2000) 1.46
Heat shock protein 27 association with the I kappa B kinase complex regulates tumor necrosis factor alpha-induced NF-kappa B activation. J Biol Chem (2003) 1.42
Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice. Cancer Res (2006) 1.26
Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci U S A (2002) 1.19
Regulation of alternative splicing of protein kinase C beta by insulin. J Biol Chem (1995) 1.18
The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood (2007) 1.12
Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia (2011) 1.06
An essential role for autophosphorylation in the dissociation of activated protein kinase C from the plasma membrane. J Biol Chem (1998) 1.06
Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}. J Leukoc Biol (2006) 1.01
cPKC-dependent sequestration of membrane-recycling components in a subset of recycling endosomes. J Biol Chem (2003) 1.01
Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol (2009) 1.00
B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII. Blood (2006) 0.98
Protein kinase Cbeta is an effective target for chemoprevention of colon cancer. Cancer Res (2009) 0.96
Activation-dependent degradation of protein kinase C eta. Oncogene (2000) 0.96
Expression of CD28 by bone marrow stromal cells and its involvement in B lymphopoiesis. J Immunol (2002) 0.94
Protein kinase C (PKC)-induced PKC degradation: a model for down-regulation. Biochem Soc Trans (1995) 0.93
Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. Leukemia (2009) 0.91
Acute hyperglycemia regulates transcription and posttranscriptional stability of PKCbetaII mRNA in vascular smooth muscle cells. FASEB J (1999) 0.86
Protein kinase C-associated kinase (PKK) mediates Bcl10-independent NF-kappa B activation induced by phorbol ester. J Biol Chem (2002) 0.86
Heterogeneity of protein kinase C beta(2) expression in lymphoid malignancies. Histopathology (2007) 0.85
Overexpression of protein kinase C-alpha and -beta isozymes by stromal dendritic cells in basal and squamous cell carcinoma. Br J Dermatol (1997) 0.80
Growth factors can protect B-chronic lymphocytic leukaemia cells against programmed cell death without stimulating proliferation. Leuk Lymphoma (1995) 0.79
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Regulation of the germinal center response by microRNA-155. Science (2007) 12.25
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol (2007) 8.92
BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Modelling Myc inhibition as a cancer therapy. Nature (2008) 5.81
Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature (2006) 5.34
A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med (2009) 5.20
Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature (2009) 5.00
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol (2013) 4.50
Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science (2003) 4.40
Cohort profile: the study of health in Pomerania. Int J Epidemiol (2010) 4.38
The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol (2010) 4.26
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A (2008) 4.26
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol (2010) 4.09
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol (2007) 4.03
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood (2002) 4.00
Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity (2006) 3.74
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med (2012) 3.63
Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol (2009) 3.58
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood (2009) 3.50
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2012) 3.43
TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature (2002) 3.21
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med (2008) 3.13
Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. J Exp Med (2009) 3.12
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet (2002) 3.10
Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol (2013) 3.10
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol (2011) 3.09
Yin Yang 1 is a critical regulator of B-cell development. Genes Dev (2007) 3.06
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A (2002) 3.05
MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer (2008) 2.76
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood (2011) 2.71
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res (2009) 2.65
The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell (2004) 2.65
miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood (2008) 2.58
Transcription factor Gfi1 regulates self-renewal and engraftment of hematopoietic stem cells. EMBO J (2004) 2.57
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood (2013) 2.53
TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol (2004) 2.51
Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat Immunol (2006) 2.48
Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood (2007) 2.46
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood (2009) 2.41
Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol (2010) 2.38
Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood (2002) 2.37
Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol (2003) 2.35
Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell (2006) 2.32
Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med (2009) 2.31
Protein kinase C theta affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells. J Exp Med (2003) 2.30
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol (2010) 2.29
Protein kinase M zeta synthesis from a brain mRNA encoding an independent protein kinase C zeta catalytic domain. Implications for the molecular mechanism of memory. J Biol Chem (2003) 2.28
Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-T MR imaging equipment. Radiology (2005) 2.25
Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol (2004) 2.21
Implications of NRAS mutations in AML: a study of 2502 patients. Blood (2006) 2.20
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica (2007) 2.19
Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes. J Clin Invest (2007) 2.17
B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood (2010) 2.17
Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. EMBO J (2007) 2.16
Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med (2010) 2.15
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet (2013) 2.14
Phosphatidylcholine synthesis for lipid droplet expansion is mediated by localized activation of CTP:phosphocholine cytidylyltransferase. Cell Metab (2011) 2.14
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol (2009) 2.09
RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood (2010) 2.08
Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother (2007) 2.05
Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet (2013) 2.05
Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med (2009) 2.03
PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol (2002) 2.03
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol (2008) 2.01
Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J Clin Invest (2006) 2.00
CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood (2003) 1.99
Association of periodontitis with the risk of oral leukoplakia. Oral Oncol (2012) 1.99
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol (2009) 1.98
Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med (2006) 1.98
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood (2009) 1.98
New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood (2008) 1.97
The transcriptional repressor Gfi1 affects development of early, uncommitted c-Kit+ T cell progenitors and CD4/CD8 lineage decision in the thymus. J Exp Med (2003) 1.96
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet (2012) 1.96
CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc Natl Acad Sci U S A (2006) 1.96
IkappaB kinase signaling is essential for maintenance of mature B cells. J Exp Med (2002) 1.93
Role of aPKC isoforms and their binding partners Par3 and Par6 in epidermal barrier formation. J Invest Dermatol (2006) 1.91
Genome-wide association studies of serum magnesium, potassium, and sodium concentrations identify six Loci influencing serum magnesium levels. PLoS Genet (2010) 1.91
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol (2008) 1.90